Please wait while the transcript is being prepared...
0:00
Hello. My name is Jochen Metzger
and I am working at
Mosaiques Diagnostics,
located in Hannover, Germany.
Mosaiques Diagnostics
is a small company
specializing in
clinical proteomics and
capillary electrophoresis-mass
spectrometry,
currently the most
advanced technology to
identify disease-specific
polypeptide biomarkers
in body fluids.
My presentation is about
clinical proteomics
in gastrointestinal cancers,
describing the results
of clinical studies
which were carried out
in close collaboration
with the Gastroenterology
Department of
the Medical School Hannover,
and under the supervision
of Tim Lankisch
and Michael Manns.
0:42
In this talk, I want to focus on
tumors of the biliary
tract and the pancreas.
The clinical studies
presented in this study
will focus on the
following clinical needs.
In the case of
cholangiocarcinoma,
it's accurate detection in
patients that present to
the gastrointestinal endoscopy
unit with suspicion of
cholangiocarcinoma due to
biliary stenosis is of
utmost importance to select
the most appropriate therapy.
Superior, early, and accurate
cholangiocarcinoma
detection is especially
required in young patients with
primary sclerosing cholangitis,
who are at risk for
this highly aggressive
type of bile duct cancer,
since this will enable
early curative treatment.
In the case of
pancreatic carcinoma,
its reliable differentiation
from chronic pancreatitis,
a long-term inflammatory
process that shows
the same signs in the pancreas,
is of high clinical value.
Moreover, in the elucidation of
underlying pathological processes
in pancreatic cancer,
progression is attempted to
provide new insights into the
treatment of this cancer.
